BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:EVO756 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of EVO756\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07616128-1364@assetmemo.bio
DTSTAMP:20261121T004530Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:EVO756: Phase 2 readout est. (NCT07616128)
DESCRIPTION:EVO756\, phase 2\, Migraine.\nStudy: Study of EVO756 in Adults 
 With Migraine\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/evo756#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07616128
URL:https://assetmemo.bio/drug/evo756#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
